<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01925911</url>
  </required_header>
  <id_info>
    <org_study_id>IPI-145-10</org_study_id>
    <nct_id>NCT01925911</nct_id>
  </id_info>
  <brief_title>Phase 1 Study in Healthy Subjects to Evaluate the Effect of IPI-145 on the Pharmacokinetics of Midazolam</brief_title>
  <acronym>DDI</acronym>
  <official_title>A Phase 1, Open-Label, Single-Sequence, 2-Period Study to Evaluate the Effect of IPI-145 on Single-Dose Pharmacokinetics of Midazolam (a CYP3A Substrate) in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Verastem, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Verastem, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the effect of IPI-145 on the pharmacokinetics of midazolam, a cytochrome P450 3A
      (CYP3A) substrate; to assess the safety and tolerability of IPI-145 when administered with
      midazolam in healthy subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  In Treatment Period 1, subjects will receive a single 2 mg oral dose of midazolam.

        -  In Treatment Period 2, on Days 2-6, the same subjects will receive twice daily (BID)
           oral doses of 25 mg IPI-145; on Day 6, subjects will receive the morning dose of 25 mg
           IPI-145 concomitantly administered with 2 mg of midazolam.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic parameters (AUC) of midazolam and 1-hydroxy-midazolam</measure>
    <time_frame>Over 24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameters (Cmax) of midazolam and 1-hydroxy-midazolam</measure>
    <time_frame>Over 24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameters (t1/2) of midazolam and 1-hydroxy-midazolam</measure>
    <time_frame>Over 24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentrations of midazolam and 1-hydroxy-midazolam</measure>
    <time_frame>Over 24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events following of administration midazolam, IPI-145 and the combination</measure>
    <time_frame>2 weeks</time_frame>
    <description>Safety Findings</description>
  </secondary_outcome>
  <enrollment type="Actual">14</enrollment>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IPI-145</intervention_name>
    <description>25 mg BID Oral Capsule</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>2 mg midazolam syrup</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy men or women of non-childbearing potential between 18-50 years of age

          -  Body Mass Index (BMI): 18.0 - 32.0 kg/m2.

          -  In good health, determined by no clinically significant findings from clinical
             evaluations

          -  Provided written informed consent prior to any study specific procedures

        Exclusion Criteria:

          -  Women of childbearing potential

          -  Evidence of clinically significant medical conditions

          -  History of gastrointestinal disease or surgery that may affect drug absorption

          -  Positive or indeterminate tuberculosis-spot test at screening

          -  Any active infection at the time of screening or admission

          -  Subjects with acute narrow-angle glaucoma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandra Willsie</last_name>
    <role>Principal Investigator</role>
    <affiliation>PRA Health Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hagop Youssoufian, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Verastem, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRA International</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 15, 2013</study_first_submitted>
  <study_first_submitted_qc>August 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2013</study_first_posted>
  <last_update_submitted>July 28, 2017</last_update_submitted>
  <last_update_submitted_qc>July 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>Healthy subjects</keyword>
  <keyword>DDI</keyword>
  <keyword>CYP3A</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

